Pfizer and GSK to battle for share of new RSV vaccine market: GlobalData EP News Bureau Jun 13, 2023 Pfizer's RSV vaccine, Abrysvo, approved by the FDA just weeks after Arexvy, is likely to show GSK significant competition
